OREANDA-NEWS  The Finnish pharmaceutical company Orion Pharma has stopped working in Russia, it follows from its financial report for the first half of the year. Orion Pharma is the main manufacturer of "Metipred" (methylprednisolone, a hormonal anti—inflammatory drug), included in the list of vital medicines.

According to a document published on its website, the company recorded a decrease in operating profit of €25 million "due to the termination of business in Russia." When exactly she left the Russian market is not specified.

As the Pharmaceutical Bulletin draws attention, the report does not say that Orion Pharma has stopped supplying medicines to Russia. However, the data of Roszdravnadzor indicate a sharp reduction in the introduction of drugs into circulation of this company. In particular, since May 2022, it has not supplied Divigel (estradiol), used for hormone replacement therapy, to Russia.

The fact that Orion Pharma, which has been operating in Russia for 15 years, has begun to liquidate the Russian office, was reported by Vedomosti sources back in October 2022. The Russian division of the pharmaceutical company "Orion Pharma" in the same month assured that it continues to work normally.